抗磷脂抗体综合征的治疗：过去五年的进展？

Treatment of the antiphospholipid antibody syndrome: progress in the last five years?

作者信息

Petri M

机构信息

Johns Hopkins University School of Medicine, 1830 E. Monument Street, Suite 7500, Baltimore, MD 21205, USA.

出版信息

Curr Rheumatol Rep. 2000 Jun;2(3):256-61. doi: 10.1007/s11926-000-0088-5.

DOI:10.1007/s11926-000-0088-5

PMID:11123068

Abstract

The gold standard for treatment of the antiphospholipid antibody syndrome (APS) after thrombosis remains high-intensity warfarin, and, in pregnancy, heparin and aspirin. Exciting developments include the potential role of hydroxychloroquine as a prophylactic drug, stem cell transplantation, and B-cell tolerance. Animal models appear to be a fruitful "proving ground" of new therapies. The introduction of revised classification criteria for APS should aid in appropriate characterization of, and selection of, patients for clinical trials.

摘要

血栓形成后抗磷脂抗体综合征（APS）的治疗金标准仍然是高强度华法林，而在妊娠期间则是肝素和阿司匹林。令人兴奋的进展包括羟氯喹作为预防药物的潜在作用、干细胞移植和B细胞耐受性。动物模型似乎是新疗法富有成效的“试验场”。APS修订分类标准的引入应有助于对患者进行适当的特征描述和选择，以开展临床试验。